Paul Beninger

Paul Beninger

(617) 636-4057
136 Harrison Avenue, Room 203
Research/Areas of Interest: . Ethical Issues in the use of CRISPR . Development process of new drugs, biologics, vaccines, and medical devices . Pharmacovigilance, including signal management and benefit-risk management . Regulatory science

Education

  • Master of Business Administration, St Joseph's University, USA, 2004
  • Doctor of Medicine, University of California Davis, USA, 1979
  • Bachelor of Arts, Claremont Mckenna College, USA, 1973

Biography

Dr. Beninger is Associate Professor of Public Health & Community Medicine at Tufts University School of Medicine, where he is the Director of the MD/MBA and MBS/MBA Programs. He has more than three decades of career experience as a regulator and member of the Senior Executive Service in the US Food and Drug Administration, as a manager and executive in the pharmaceutical industry and as a member of the academic community.

Dr. Beninger began his career in drug development in 1987 at the US Food and Drug Administration, first as a reviewer and manager for drugs against HIV/AIDS and opportunistic infections and then as a division director for medical devices. He joined Merck & Company in 1995 and developed experience in regulatory affairs, medical affairs and drug safety in the areas of anti-infective drug and biological products, vaccines, anti-diabetic drug products and oncology drug products, before joining Genzyme as vice-president of pharmacovigilance in 2006; Genzyme was acquired by Sanofi in 2011. Dr. Beninger retired from Genzyme-Sanofi in April, 2017.

Dr. Beninger trained in internal medicine and infectious diseases. He received his MD from the University of California, Davis, his BA from Claremont McKenna College in Claremont, California, his MBA from St Joseph's University in Philadelphia, Pennsylvania, and his graduate certificate in epidemiology from Tufts.

Dr. Beninger has published and spoken extensively on regulatory science, drug and vaccine safety, and pharmacovigilance. He is a topics editor (pharmacovigilance and pharmacoepidemiology) for Clinical Therapeutics, and a fellow of the American College of Physicians and the Infectious Disease Society of America.